The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study
Top Cited Papers
Open Access
- 17 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hepatology
- Vol. 54 (4), 1208-1216
- https://doi.org/10.1002/hep.24491
Abstract
Information on the long‐term prognosis of nonalcoholic fatty liver disease (NAFLD) is limited. We sought to describe the long‐term morbidity and mortality of patients with NAFLD with advanced fibrosis or cirrhosis by prospectively studying 247 such patients from four international centers (in Australia, USA, UK and Italy). Their natural history was then compared with 264 patients with HCV infection who were either naïve or non‐responders to treatment. Both cohorts were Child‐Pugh class A and had advanced fibrosis (stage 3) or cirrhosis (stage 4) confirmed by liver biopsy at enrollment. In the NAFLD cohort, followed up for a mean of 85.6 months (range, 6‐297), there were 48 (19.4%) liver‐related complications and 33 (13.4%) deaths or liver transplants. In the HCV cohort, followed up for 74.9 months (mean; range, 6‐238), there were 47 (16.7%) liver‐related complications and 25 (9.4%) deaths or liver transplants. When adjusting for baseline differences in age and gender, the cumulative incidence of liver‐related complications was lower in the NAFLD than the HCV cohort (P = 0.03), including incident hepatocellular cancer (6 versus 18; P = 0.03), but that of cardiovascular events (P = 0.17) and overall mortality (P = 0.6) were similar in both groups. In the NAFLD cohort, platelet count, stage 4 fibrosis, lowered platelet count, and lowered serum cholesterol and alanine aminotrasferase (ALT) levels were associated with liver‐related complications; an aspartate aminotransferase/ALT ratio >1 and older age were associated with overall mortality, and higher serum bilirubin levels and stage 4 fibrosis were associated with liver‐related mortality. Conclusions: Patients with NAFLD with advanced fibrosis or cirrhosis have lower rates of liver‐related complications and hepatocellular cancer than corresponding patients with HCV infection, but similar overall mortality. Some clinical and laboratory features predict liver‐related complications and other outcomes in patients with NAFLD. (HEPATOLOGY 2011;54:1208–1216)Keywords
This publication has 32 references indexed in Scilit:
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2010
- Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance?Journal of Hepatology, 2010
- The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 yearsGut, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Benefits of lifestyle modification in NAFLDGut, 2007
- Current and novel therapies for the treatment of nonalcoholic steatohepatitisHepatology International, 2007
- The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLDJournal of Hepatology, 2007
- Non-alcoholic fatty liver disease: current concepts and management strategiesClinical Medicine, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseJournal of Hepatology, 2005
- The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsiesJournal of Hepatology, 2005